Peg-filgrastim — Competitive Intelligence Brief

Peg-filgrastim (Peg-filgrastim) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: G-CSF agonist. Area: Oncology.

phase 3 G-CSF agonist G-CSFR Oncology Small molecule

Target snapshot

Peg-filgrastim (Peg-filgrastim) — Asan Medical Center. Peg-filgrastim stimulates the production of white blood cells, specifically neutrophils, to help the body fight infection.

Comparator set (3 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Peg-filgrastim TARGET	Peg-filgrastim	Asan Medical Center	phase 3	G-CSF agonist	G-CSFR
filgrastim and pegylated filgrastim	filgrastim and pegylated filgrastim	Chinese Academy of Medical Sciences	phase 3	G-CSF agonist	G-CSFR
pegylated filgrastim and filgrastim	pegylated filgrastim and filgrastim	Chinese Academy of Medical Sciences	phase 3	G-CSF agonist	G-CSF receptor
YPEG-rhG-CSF	YPEG-rhG-CSF	Xiamen Amoytop Biotech Co., Ltd.	phase 3	G-CSF agonist	G-CSF receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (G-CSF agonist class)

1. Chinese Academy of Medical Sciences · 2 drugs in this class
2. Asan Medical Center · 1 drug in this class
3. Centre Leon Berard · 1 drug in this class
4. Recardio, Inc. · 1 drug in this class
5. Xiamen Amoytop Biotech Co., Ltd. · 1 drug in this class